Sodium risedronate-loaded poly(ε-caprolactone) nanoparticles: Development, physicochemical characterization, and in vitro drug release study



osteoporosis, sodium risedronate, nanostructured systems, solvent emulsification/evaporation method.


Population in all over the world is affected by bone diseases, such as osteoporosis and loss bone tissue. Sodium risedronate (Na-Ris) is one of the most used drugs to its treatment. However, it has low oral bioavailability and exhibits many side effects. In order to overcome these limitations, the search for new dosage forms is necessary. One of these alternatives is the development of nanoparticles, which are able to transport the drug to its target directly, promoting maximization of the therapeutic efficiency and minimization of the toxicity. Due to its great versatility, these systems can be applied to an assorted administration routes, such as oral, pulmonary, intravenous, among others. Thus, the objective of this study was to develop and characterize Na-Ris-loaded nanoparticles, as well as determine the drug release profile. Methods: Nanoparticles were prepared by solvent emulsification/evaporation method and characterized by mean size, polydispersity index, zeta potential, granulometric distribution, drug content and encapsulation efficiency. Afterwards, in vitro drug release was performed using the dialysis bag technique as well as the release kinetics were also studied. Results: The developed system has shown mean size of 193 ± 14 nm and polydispersity index around 0.2. Zeta potential was -9.76 ± 0,52 mV and slightly acid values for pH. The granulometric distribution demonstrated nanoparticles with a narrow size distribution and the absence of particles in the micrometer range. Regarding the in vitro release, the drug was released completely from the system in 240 minutes and the release kinetics has follow the zero-order equation. Final considerations: Thus, a nanocarrier containing a water-soluble drug was successfully developed, presenting adequate physicochemical characteristics, which can be promising for biological evaluations.


Não há dados estatísticos.


Appelman-Dijkstra NM, Papapoulos SE. Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs. 2015;75(10):1049–58. At: 10.1007/s40265-015-0417-7

Radominski SC, Bernardo W, Paula AP de, Albergaria B-H, Moreira C, Fernandes CE, et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol (English Ed. 2017;57:452–66. At: 10.1016/j.rbre.2017.07.001

Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis [Internet]. Vol. 71, Drugs. Drugs; 2011. p. 791–814. At: 10.2165/11585470-000000000-00000

Dingemans SA, Lodeizen OAP, Goslings JC, Schepers T. Reinforced fixation of distal fibula fractures in elderly patients; A meta-analysis of biomechanical studies. Vol. 36, Clinical Biomechanics. Elsevier Ltd; 2016. p. 14–20.

Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42(3):175–95. At: 10.1016/S0169-409X(00)00061-2

Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. Relationship between Gastrointestinal Events and Compliance with Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. Clin Ther. 2016;38(5):1074–80. At: 10.1016/j.clinthera.2016.03.027

Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease [Internet]. Vol. 23, Pharmaceutical Research. Springer Science and Business Media Deutschland GmbH; 2006. p. 1417–50. At: 10.1007/s11095-006-0284-8

Zielinska A, Carreiró F, Oliveira AM, Neves A, Pires B, Nagasamy Venkatesh D, et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology [Internet]. Vol. 25, Molecules. MDPI AG; 2020. At: 10.3390/molecules25163731

Deng S, Gigliobianco MR, Censi R, Di Martino P. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: Current status, challenges and opportunities [Internet]. Vol. 10, Nanomaterials. MDPI AG; 2020. At: 10.3390/nano10050847

Moritz M, Geszke-Moritz M. Mesoporous materials as multifunctional tools in biosciences: Principles and applications. Vol. 49, Materials Science and Engineering C. Elsevier Ltd; 2015. p. 114–51.

Ferreira LMLM, Cervi VFVF, Sari MHMMHM, Barbieri AVAV, Ramos APAP, Copetti PMPM, et al. Diphenyl diselenide loaded poly(ε-caprolactone) nanocapsules with selective antimelanoma activity: Development and cytotoxic evaluation. Mater Sci Eng C. 2018;91(September 2017):1–9. At: 10.1016/j.msec.2018.05.014

Gehrcke M, Giuliani LMLM, Ferreira LMLM, Barbieri AVAV, Sari MHMMHM, da Silveira EFEF, et al. Enhanced photostability, radical scavenging and antitumor activity of indole-3-carbinol-loaded rose hip oil nanocapsules. Mater Sci Eng C. 2017;74:279–86. At: 10.1016/j.msec.2016.12.006

Bitencourt PER, Ferreira LM, Cargnelutti LO, Denardi L, Boligon A, Fleck M, et al. A new biodegradable polymeric nanoparticle formulation containing Syzygium cumini: Phytochemical profile, antioxidant and antifungal activity and in vivo toxicity. Ind Crops Prod. 2016;83:400–7. At: 10.1016/j.indcrop.2016.01.007

Schaffazick SR, Guterres SS, De Lucca Freitas L, Pohlmann AR. Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration. Vol. 26, Quimica Nova. Sociedade Brasileira de Quimica; 2003. p. 726–37.

Rigon C, Giuliani LM, Fabiele M, Stangarlin L, Mattiazzi J. SISTEMAS NANOESTRUTURADOS CONTENDO ÓLEO DE LINHAÇA : desenvolvimento tecnológico e caracterização físico-química de nanoemulsões e nanocápsulas poliméricas NANOSTRUTURED SYSTEMS CONTAINING LINSEED OIL : technological development and physicochemical charac. Saúde St Maria. 2017;43(1):153–61.

Bitencourt PERPER, Cargnelutti LOLO, Stein CSCS, Lautenchleger R, Ferreira LMLM, Sangoi M, et al. Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicansinfected diabetic rats. Pharm Biol. 2017;55(1):1082–8. At: 10.1080/13880209.2017.1283338

Bitencourt PERPER, Cargnelutti LOLO, Stein CSCS, Lautenchleger R, Ferreira LMLM, Sangoi M, et al. Anti-inflammatory action of seed extract and polymeric nanoparticles of syzygium cumini in diabetic rats infected with candida albicans. J Appl Pharm Sci. 2017;7(1):7–016.

Akbari B, Tavandashti MP, Zandrahimi M. Particle size characterization of nanoparticles- a practicalapproach. Iran J Mater Sci Eng. 2011;8(2):48–56.

Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000;199(1):95–110.

Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RC, et al. Poly(ε-caprolactone) microcapsules and nanocapsules in drug delivery [Internet]. Vol. 10, Expert Opinion on Drug Delivery. Expert Opin Drug Deliv; 2013. p. 623–38. At: 10.1517/17425247.2013.769956

Fontana MC, Beckenkamp A, Buffon A, Beck RCR. Controlled release of raloxifene by nanoencapsulation: Effect on in vitro antiproliferative activity of human breast cancer cells. Int J Nanomedicine. 2014;9(1):2979–91.

Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery [Internet]. Vol. 385, International Journal of Pharmaceutics. Elsevier B.V.; 2010. p. 113–42. At: 10.1016/j.ijpharm.2009.10.018

Kotak DJ, Devarajan P V. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). Nanomedicine Nanotechnology, Biol Med. 2020;24:102153.

Rawat P, Ahmad I, Thomas SC, Pandey S, Vohora D, Gupta S, et al. Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. Int J Pharm. 2016;506(1–2):253–61. At: 10.1016/j.ijpharm.2016.04.049

Elnaggar YSR, Omran S, Hazzah HA, Abdallah OY. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm. 2019;564:410–25. At: 10.1016/j.ijpharm.2019.04.069

Nasr M, Awad GAS, Mansour S, Shamy A Al, Mortada ND. Hydrophilic versus hydrophobic porogens for engineering of poly(lactide-co-glycolide) microparticles containing risedronate sodium. Pharm Dev Technol. 2013;18(5):1078–88. At: 10.3109/10837450.2012.693507

Nasr M, Taha I, Hathout RM. Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route. Drug Deliv. 2013;20(8):311–8. At: 10.3109/10717544.2013.835160

Dissette V, Bozzi P, Bignozzi CA, Dalpiaz A, Ferraro L, Beggiato S, et al. Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates. Eur J Pharm Sci. 2010;41(2):328–36. At: 10.1016/j.ejps.2010.06.020

Khajuria DK, Disha C, Vasireddi R, Razdan R, Mahapatra DR. Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Mater Sci Eng C. 2016;63:78–87. At: 10.1016/j.msec.2016.02.062




Como Citar

Gomes, F. P., Cruz, L., & Ferreira, L. M. (2022). Sodium risedronate-loaded poly(ε-caprolactone) nanoparticles: Development, physicochemical characterization, and in vitro drug release study. Saúde (Santa Maria), 48(1). Recuperado de

Artigos mais lidos pelo mesmo(s) autor(es)